{"id":"cfc184a7-b078-5e2d-ae5f-b77a8f4bd279","stable_key":"4fef8d72-f107-5eb5-b2fb-483ca85465e0:k2-vitak-exposure","predicate":"increases","statement":"Median plasma MK-7 increased from 0.50 to 6.56 micrograms/L in the active-treatment group.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"dd32edf8-7012-5ebe-b29e-4cabcf065219","mechanism_event_label":"The trial documented exposure as well as its imaging outcome.","subject":{"id":"a3ff2a7b-69f3-5098-8fac-fb8d7668397b","slug":"menaquinone-7","display_name":"Menaquinone-7 / MK-7","entity_type_key":"small_molecule"},"object":{"id":"41efbc28-e370-5f6d-8cd9-b5e26f0e89e8","slug":"mk7-serum-concentration","display_name":"Serum menaquinone-7 concentration","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"dd32edf8-7012-5ebe-b29e-4cabcf065219","stable_key":"4fef8d72-f107-5eb5-b2fb-483ca85465e0:k2-vitak-exposure-event","event_type":"observed_intervention","label":"The trial documented exposure as well as its imaging outcome.","description":"Median plasma MK-7 increased from 0.50 to 6.56 micrograms/L in the active-treatment group.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"a3ff2a7b-69f3-5098-8fac-fb8d7668397b","slug":"menaquinone-7","display_name":"Menaquinone-7 / MK-7","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"41efbc28-e370-5f6d-8cd9-b5e26f0e89e8","slug":"mk7-serum-concentration","display_name":"Serum menaquinone-7 concentration","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/k2-research/42268593.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"8bd6d3cb0722f549b8a9c8f06feba3165dfd421c4ce0658b75b90a6e64e84a4b\", \"start_char\": 0, \"end_char\": 2890, \"text_sha256\": \"8bd6d3cb0722f549b8a9c8f06feba3165dfd421c4ce0658b75b90a6e64e84a4b\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Two-year randomized placebo-controlled VitaK-CAC trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"MK-7 360 micrograms/day; baseline CAC 50–400","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Published 2026; imaging surrogate, not demonstrated fewer infarctions, improved plaque stability or arterial calcium removal. One author disclosed grants from Gnosis and shares in Coagulation Profile outside this work.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Vitamin K2 research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"k2","display_name":"Vitamin K2 / menaquinone family","entity_type_key":"chemical_species"}},{"dimension":"organism","value_text":"180 randomized symptomatic coronary-disease patients; 85 received MK-7 and 82 placebo","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The trial documented exposure as well as its imaging outcome.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[k2-p42268593] Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification: A Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/42268593/ DOI: 10.1001/jamacardio.2026.1279","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Coronary CT calcium score and calcium mass","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"52c44820-ea02-5449-a18a-b068f10fea77","evidence_kind":"source_excerpt","locator":"Lines 1241-1252","start_line":1241,"end_line":1252,"excerpt":"### k2-vitak-exposure\nMedian plasma MK-7 increased from 0.50 to 6.56 micrograms/L in the active-treatment group.\nCondition category: normal\nnutrient_topic: Vitamin K2 research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The trial documented exposure as well as its imaging outcome.\norganism: 180 randomized symptomatic coronary-disease patients; 85 received MK-7 and 82 placebo\ntissue_or_cell_type: Coronary CT calcium score and calcium mass\nexperimental_model: Two-year randomized placebo-controlled VitaK-CAC trial\nlimitations: Published 2026; imaging surrogate, not demonstrated fewer infarctions, improved plaque stability or arterial calcium removal. One author disclosed grants from Gnosis and shares in Coagulation Profile outside this work.\nexposure: MK-7 360 micrograms/day; baseline CAC 50–400\nevidence_span: {\"source_cache\": \"artifacts/k2-research/42268593.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"8bd6d3cb0722f549b8a9c8f06feba3165dfd421c4ce0658b75b90a6e64e84a4b\", \"start_char\": 0, \"end_char\": 2890, \"text_sha256\": \"8bd6d3cb0722f549b8a9c8f06feba3165dfd421c4ce0658b75b90a6e64e84a4b\"}\n[k2-p42268593] Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification: A Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/42268593/ DOI: 10.1001/jamacardio.2026.1279","model_system":"Two-year randomized placebo-controlled VitaK-CAC trial","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [k2-p42268593] Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification: A Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/42268593/ DOI: 10.1001/jamacardio.2026.1279","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"dfeae572-af3d-5042-a10e-e67596f9ab28","stable_key":"import-4fef8d72-f107-5eb5-b2fb-483ca85465e0","title":"Vitamin K2: menaquinone forms, carboxylation, recycling and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"dc31aff21110d09b025c177e03b4c5ca8349d52bf5f962285fdbfcf660c0e4f6","revision_id":"850887db-34f6-55aa-9d3e-b8fd3a4a5de3","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}